Image

Middle East and Africa Mild Cognitive Impairment (MCI) Treatment Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Feb 2022
  • MEA
  • 350 Pages
  • No of Tables: 183
  • No of Figures: 53

Middle East and Africa Mild Cognitive Impairment (MCI) Treatment Market, By Disease Type (Amnestic MCI, Non-Amnestic MCI), Treatment Type (Medications, Therapy), Route Of Administration (Oral, Parenteral, Others), Drug Type (Branded, Generics), Gender Type (Male, Female), Age Type (Child, Adult, Geriatric), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacy), Country (South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel, and Rest of Middle East and Africa) – Industry Trends & Forecast to 2029

Middle East and Africa Mild Cognitive Impairment (MCI) Treatment Market

Market Analysis and Insights: Middle East and Africa Mild Cognitive Impairment (MCI) Treatment Market

The mild cognitive impairment (MCI) treatment market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.4% in the forecast period of 2022 to 2029 and is expected to reach USD 3,981.49 thousand by 2029. Wide portfolio offered by major players and growing awareness of mild cognitive impairment is expected to act as driver for the market growth.

Mild cognitive impairment (MCI) is an early stage of memory loss or other cognitive ability loss (such as language or visual/spatial perception) in individuals who maintain the ability to perform most activities of daily living independently. MCI can develop for multiple reasons, and individuals living with MCI may develop dementia. MCI can be an early stage of the disease continuum for neurodegenerative diseases, including Alzheimer's. In some individuals, MCI reverts to normal cognition or remains stable.

Mild cognitive impairment (MCI) is characterized by impairment in a single cognitive domain, usually memory (amnestic MCI), or moderate impairment in several cognitive domains. The prevalence of MCI among individuals living in long-term care settings varies from 5% to 10% in many nursing homes to up to 30%. The most frequently encountered form of MCI is the amnestic type. Less common variants of MCI present with localized impairment of other cognitive domains such as executive dysfunction in Frontotemporal lobar degeneration (FTLD).

Major factors driving the growth of the global mild cognitive impairment (MCI) treatment market are an increase in the older patients population, ongoing research to find the perfect and effective cure is expected to drive the market's growth in the coming time. However, the high cost of therapies procedures and product-associated adverse risks may hamper the market growth.

The mild cognitive impairment (MCI) treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the Mild Cognitive Impairment (MCI) Treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Middle East and Africa Mild Cognitive Impairment (MCI) Treatment Market

Mild Cognitive Impairment (MCI) Treatment Market Scope and Market Size

The mild cognitive impairment (MCI) treatment market is segmented on basis of disease type, treatment type, route of administration, drug type, gender, age, distribution channel, and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • Based on disease type, the mild cognitive impairment (MCI) treatment market is segmented into amnestic MCI and non-amnestic MCI. In 2022, the amnestic MCI segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to the increase in the older population across the globe.
  • Based on treatment type, the mild cognitive impairment (MCI) treatment market is segmented into medication and therapy. In 2022, the medication segment is expected to dominate the global mild cognitive impairment (MCI) treatment market due to its immediate and effective impact on MCI symptoms.
  • Based on route of administration, the mild cognitive impairment (MCI) treatment market is segmented into oral and parenteral, and others. In 2022, the oral segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to the non-invasive, high patient compliance, convenience handling, and not requiring any specific sterile conditions.
  • Based on drug type, the mild cognitive impairment (MCI) treatment market is segmented into branded and generics. In 2022, the generics segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to the cost-effectiveness compared to branded drugs.
  • Based on gender, the mild cognitive impairment (MCI) treatment market is segmented into male and female. In 2022, the male segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to a surge in mental health complications observed in the male population.
  • Based on age, the mild cognitive impairment (MCI) treatment market is segmented into child, adult, and geriatric. In 2022, the geriatric segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to a surge in vulnerable older people population with the highest rate of increase in the Asian region.
  • Based on end users, the mild cognitive impairment (MCI) treatment market is segmented into hospitals, specialty clinics, homecare, and others. In 2022, the hospital segment is expected to dominate the global mild cognitive impairment (MCI) treatment market due to increased awareness regarding better and more effective treatment during hospital stays.
  • Based on distribution channel, the mild cognitive impairment (MCI) treatment market is segmented into hospital pharmacies, retail pharmacy. In 2022, the hospital pharmacy segment is expected to dominate the global mild cognitive impairment (MCI) treatment market due to increased interaction with certified prescribers and health professionals to use antipsychotic drugs and guaranteed payment.

Mild Cognitive Impairment (MCI) Treatment Market Country Level Analysis

The mild cognitive impairment (MCI) treatment market is analyzed and market size information is provided by the country, disease type, treatment type, route of administration, drug type, gender type, age, distribution channel, and end users as referenced above.

The countries covered in the mild cognitive impairment (MCI) treatment market report are the South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait and rest of Middle East and Africa.

South Africa is expected to dominate the mild cognitive impairment (MCI) treatment market due to the increasing geriatric population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing strategic activities by major market players to enhance the awareness for mild cognitive impairment (MCI) treatment, is boosting the market growth of mild cognitive impairment (MCI) treatment market.

The mild cognitive impairment (MCI) treatment market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.

Competitive Landscape and Mild Cognitive Impairment (MCI) Treatment Market Share Analysis

Mild cognitive impairment (MCI) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to mild cognitive impairment (MCI) treatment market.

Some of the major players operating in the mild cognitive impairment (MCI) treatment market are Pfizer Inc., F. Hoffman La Roche Ltd, Novartis AG, Accord UK Ltd, Dr. Reddy’s laboratories Ltd, Hikma Pharmaceuticals PLC, Viatris Inc., Eisai. Co. Ltd., Sun Pharmaceuticals ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt, AstraZeneca, Cipla Inc., Takeda Pharmaceutical Company Limited, Allergan Aesthetics, Lupin, Jubilant Pharmova Limited, Lannett, Aurobindo Pharma, UCB S.A., Belgium, and WOCKHARDT, among others.

For instance,

  • In July 2021, FDA approved Biogen Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company footprints in the mild cognitive impairment (MCI) treatment market which also provides the benefit for organization’s profit growth.

Customization Available: Middle East and Africa Mild Cognitive Impairment (MCI) Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 COMMON BENZODIAZEPINES AVAILABLE IN THE U.S.-

TABLE 2 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 3 MIDDLE EAST & AFRICA AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4 MIDDLE EAST & AFRICA NON-AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 5 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 6 MIDDLE EAST & AFRICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 7 MIDDLE EAST & AFRICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 8 MIDDLE EAST & AFRICA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 9 MIDDLE EAST & AFRICA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 10 MIDDLE EAST & AFRICA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 11 MIDDLE EAST & AFRICA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 12 MIDDLE EAST & AFRICA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 13 MIDDLE EAST & AFRICA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 14 MIDDLE EAST & AFRICA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 15 MIDDLE EAST & AFRICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 16 MIDDLE EAST & AFRICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 17 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 18 MIDDLE EAST & AFRICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 19 MIDDLE EAST & AFRICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 20 MIDDLE EAST & AFRICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 21 MIDDLE EAST & AFRICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 22 MIDDLE EAST & AFRICA OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 24 MIDDLE EAST & AFRICA GENERICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 25 MIDDLE EAST & AFRICA BRANDED IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 26 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 27 MIDDLE EAST & AFRICA MALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 28 MIDDLE EAST & AFRICA FEMALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 29 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 30 MIDDLE EAST & AFRICA GERIATRIC IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31 MIDDLE EAST & AFRICA ADULT IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 32 MIDDLE EAST & AFRICA CHILD IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 33 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 34 MIDDLE EAST & AFRICA HOSPITALS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35 MIDDLE EAST & AFRICA SPECIALITY CLINICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 36 MIDDLE EAST & AFRICA HOMECARE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37 MIDDLE EAST & AFRICA OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 38 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 39 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40 MIDDLE EAST & AFRICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 41 MIDDLE EAST & AFRICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 42 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 43 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 44 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 45 MIDDLE EAST AND AFRICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 46 MIDDLE EAST AND AFRICA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 47 MIDDLE EAST AND AFRICA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 48 MIDDLE EAST AND AFRICA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 49 MIDDLE EAST AND AFRICA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 50 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 51 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 52 MIDDLE EAST AND AFRICA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 53 MIDDLE EAST AND AFRICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 54 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 55 MIDDLE EAST AND AFRICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 56 MIDDLE EAST AND AFRICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 57 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 58 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 59 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 60 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 61 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 62 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 63 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 64 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 65 SOUTH AFRICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 66 SOUTH AFRICA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 67 SOUTH AFRICA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 68 SOUTH AFRICA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 69 SOUTH AFRICA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 70 SOUTH AFRICA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 71 SOUTH AFRICA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 72 SOUTH AFRICA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 73 SOUTH AFRICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 74 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 75 SOUTH AFRICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 76 SOUTH AFRICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 77 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 78 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 79 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 80 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 81 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 82 SOUTH AFRICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 83 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 84 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 85 EGYPT MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 86 EGYPT CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 87 EGYPT BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 88 EGYPT GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 89 EGYPT MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 90 EGYPT PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 91 EGYPT ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 92 EGYPT ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 93 EGYPT THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 94 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 95 EGYPT ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 96 EGYPT PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 97 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 98 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 99 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 100 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 101 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 102 EGYPT RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 103 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 104 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 105 SAUDI ARABIA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 106 SAUDI ARABIA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 107 SAUDI ARABIA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 108 SAUDI ARABIA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 109 SAUDI ARABIA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 110 SAUDI ARABIA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 111 SAUDI ARABIA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 112 SAUDI ARABIA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 113 SAUDI ARABIA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 114 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 115 SAUDI ARABIA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 116 SAUDI ARABIA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 117 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 118 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 119 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 120 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 121 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 122 SAUDI ARABIA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 123 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 124 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 125 UAE MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 126 UAE CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 127 UAE BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 128 UAE GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 129 UAE MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 130 UAE PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 131 UAE ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 132 UAE ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 133 UAE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 134 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 135 UAE ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 136 UAE PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 137 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 138 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 139 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 140 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 141 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 142 UAE RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 143 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 144 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 145 ISRAEL MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 146 ISRAEL CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 147 ISRAEL BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 148 ISRAEL GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 149 ISRAEL MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 150 ISRAEL PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 151 ISRAEL ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 152 ISRAEL ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 153 ISRAEL THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 154 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 155 ISRAEL ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 156 ISRAEL PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 157 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 158 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 159 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 160 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 161 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 162 ISRAEL RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 163 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 164 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 165 KUWAIT MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 166 KUWAIT CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 167 KUWAIT BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 168 KUWAIT GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 169 KUWAIT MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 170 KUWAIT PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 171 KUWAIT ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 172 KUWAIT ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 173 KUWAIT THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 174 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 175 KUWAIT ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 176 KUWAIT PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 177 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 178 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 179 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 180 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 181 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 182 KUWAIT RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 183 REST OF MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

Middle East and Africa Mild Cognitive Impairment (MCI) Treatment Market is growing with a CAGR of 6.4% during the forecast period of 2022 to 2029.
Middle East and Africa Mild Cognitive Impairment (MCI) Treatment Market value of USD 3,981.49 thousand during the forecast period of 2022 to 2029.
The mild cognitive impairment (MCI) treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market.
The major players operating in the mild cognitive impairment (MCI) treatment market are Pfizer Inc., F. Hoffman La Roche Ltd, Novartis AG, Accord UK Ltd, Dr. Reddy’s laboratories Ltd, Hikma Pharmaceuticals PLC, Viatris Inc., Eisai. Co. Ltd., Sun Pharmaceuticals ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt, AstraZeneca, Cipla Inc., Takeda Pharmaceutical Company Limited, Allergan Aesthetics, Lupin, Jubilant Pharmova Limited, Lannett, Aurobindo Pharma, UCB S.A., Belgium, and WOCKHARDT, among others.